Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer

Fig. 1

(A) Kaplan-Meier estimates of progression-free survival (mPFS = 71 mon) of all patients who received either upfront combination or sequential treatment with afatinib and ramucirumab (n = 33 patients); (B) Kaplan-Meier estimates of progression-free survival in patients received sequential (blue; mPFS 71 mon; n = 11) and upfront combination therapy (green; mPFS 30 mon; n = 22). PFS, progression-free survival; (C) Kaplan-Meier estimates of overall survival in patients received sequential (blue; mOS not defined mon; n = 11) and upfront combination therapy (green; mOS 30 mon; n = 22)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us